Register for our free email digests:
Latest From Intercytex
Investors like to be informed. So it is more than a little frustrating when public companies' clinical trial announcements omit important details; the way the trial was conducted, for instance, or the type of statistical analysis or the nature of the control with which a treatment was compared (scripintelligence.com, 16 July 2013).
Yesterday was the 92nd anniversary of the signing of the armistice that brought the hostilities of the First World War formally to an end. Coincidentally, it also marked the re-emergence of the UK-based regenerative medicine company Intercytex, which announced that its lead product, the cell therapy Vavelta, is to be evaluated by the US military to help treat injured soldiers.
- Gene Therapy, Cell Therapy
- Large Molecule
- Therapeutic Areas
- Wound Healing & Tissue Repair
- Western Europe
- Parent & Subsidiaries
- Senior Management
Nick Higgins, CEO
Richard Moulson, CFO
Paul Kemp, CSO
Jan Benschop, VP, Commercial Dev.
- Contact Info
Phone: (44) 161 904 4500
St. John's Innovation Centre
Cambridge, CB4 0WS
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.